Introduction {#s1}
============

Since 1980, the incidence of obesity has increased throughout the world (Stevens et al., [@B32]; Ng et al., [@B26]). The onset of obesity involves the interaction between genetic and environmental factors (Contaldo and Pasanisi, [@B7]; Ussar et al., [@B34]). Genome Wide Association Studies (GWASs) have successfully identified many genetic variations associated with human complex diseases and provide crucial new insights about underlying molecular mechanisms (De La Vega et al., [@B12]; Fall and Ingelsson, [@B17]; Winham et al., [@B38]; Evangelou et al., [@B15]). Until now, the largest obesity GWAS study has identified 97 body mass index (BMI) associated loci (*P* ≤ 5 × 10^−8^) from up to 339,224 individuals. However, most of the genetic susceptibility remains unclear (Locke et al., [@B20]).

Existing evidence suggests that obesity is a result of interactions between genetic and environmental factors (Marti et al., [@B23]). DNA methylation provides a molecular mechanism for the interaction between the environment and obesity, in that it may affect individual susceptibility to obesity by altering the gene expression. In recent years, the association between DNA methylation and obesity has intensively been studied (van Dijk et al., [@B35]; Dhana et al., [@B13]; Wang et al., [@B37]). For example, a genome-wide DNA methylation association study in obesity that recruited 5,387 individuals, identified 278 CpGs associated with BMI (Wahl et al., [@B36]). The associated CpGs have provided wider insight in addition to previous genetic studies. On the other side, the numerous associated CpGs has made it difficult for functional investigations using cell and animal models.

In this study, we applied an integrative analysis approach, to prioritize genes with more relevance from several associated CpGs. Using this approach, we identified *SOCS3* as a promising candidate for mechanism studies and drug development. This approach can also be adapted to genome-wide DNA methylation studies of other diseases.

Methods {#s2}
=======

The integrative analysis approach included three components. The first component was to nominate the candidate CpGs by combining the association results from previous studies of peripheral blood samples (Steps 1--4, Figure [1](#F1){ref-type="fig"}). The second component was to estimate the functional relevance of the candidates through pathway enrichment analysis (Step 5). The third component was to validate that the genes affiliated with candidate CpGs were differentially expressed in adipose tissues (Step 6). Finally, the evidence from these components were put together and the genes with positive support from all components were considered and prioritized by our approach (Step 7).

![The flow chart of the intergrative analysis. The circled numbers represent the steps in the pipeline.](fgene-09-00663-g0001){#F1}

Literature Search
-----------------

The literature search was conducted in the PubMed database using the keywords "CpG", "DNA methylation" and "obesity" to capture all articles published from 2014 to 2018. We applied an English language restriction to our search results.

Inclusion Criteria and Data Extraction
--------------------------------------

Both cohort studies and case-control studies reporting the association between DNA methylation and obesity (as measured by BMI) were included in this meta-analysis. Studies that used samples from cancer patients were not included. We further excluded the studies that used non-human subjects.

The full text of each article was carefully read to determine whether studies should be included. Once included, data were extracted from the articles, including the publication year, participant characteristics, sample size, association *p*-value, and the effect size.

Meta-Analysis
-------------

We employed a sample-size weighted strategy to combine the *p* values reported in the included studies, taking into consideration the direction of the association effect size. This strategy was implemented using R software (<https://www.r-project.org/>). In this meta-analysis the CpG site with *p* value less than 1.03 × 10^−7^ (Bonferroni correction based on 485,577 CpGs designed in Illumina HM450K array) and with effect sizes consistent with the direction across all included studies, were considered as significant.

Pathway Enrichment Analysis
---------------------------

We investigated the enrichment of the affiliated genes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, using the Metascape online software (<http://metascape.org>; Tripathi et al., [@B33]). The genes were annotated using the default resources provided by Metascape. KEGG pathways were reduced using the default settings (the number of gene hits ≥3, enrichment *p*-value ≤ 0.05 and enrichment statistics ≥1.5). A FDR *p*-value ≤ 0.05 was taken to declare a significant enrichment.

Differential Expression Analysis in Adipose Tissues
---------------------------------------------------

We aimed to investigate whether the associated genes were differentially expressed in the SAT and VAT of obesity patients, by comparing their gene transcription levels with normal individuals. This analysis was performed using the GEO2R tool (<https://www.ncbi.nlm.nih.gov/geo/geo2r/>) on two datasets, GSE2508 (10 obese vs. 10 lean) and GSE88837 (15 obese vs. 15 lean) for the SAT and VAT, respectively. The gene transcription levels were assayed using Affymetrix Human Genome U95 V2 and U133 arrays. The differential gene expression in obese samples was identified using the Bayesian estimation by GEO2R. Transcription level data of each sample was queried from the GEO database (Davis and Meltzer, [@B8]). Empirical Bayes statistics were calculated using the R package "limma" (Smyth, [@B31]; Ritchie et al., [@B29]). The fold change of DNA methylation was calculated using the group mean. *P* value ≤ 0.05 and \|log~2~ (fold change)\| ≥1 were used as criteria for differentially expressed genes. CpGs which were differentially expressed in both tissue types were identified as relevant loci.

The DNA Methylation Associated With Obesity in Human VAT and Liver Tissue
-------------------------------------------------------------------------

The DNA methylation of the included studies was all measured in peripheral blood, but the DNA methylation in peripheral blood may be different from that in the metabolic tissues. To test whether the association in peripheral blood samples can be transferred into obesity related tissue, we tested the association of the significant CpGs in human VAT and liver tissue, using two GEO datasets, GSE88940 (10 obese vs. 10 normal VAT samples) and GSE65057 (8 obese vs. 7 normal liver samples), respectively.

Results {#s3}
=======

Characteristic of Individual Studies
------------------------------------

According to the keywords "CpG", "DNA methylation" and "obesity", a total of 350 related articles were retrieved. Two hundred and seventy studies were excluded based on the title and abstract, as they were inconsistent with inclusion criteria, leaving 80 articles. Of those, 67 articles were excluded after a full-text review. As a result, 13 articles were included in the analysis. The reason for the exclusion of most articles was because they were functional studies in cells or animals. The basic characteristics of the included studies are detailed in Table [1](#T1){ref-type="table"}.

###### 

Characteristics of the included genome-wide DNA methylation studies.

  **References**             **Corhort source**        **Ethnicity**   **Subjects**   **Body mass Index(kg/m^**2**^)[^a^](#TN1){ref-type="table-fn"}**
  -------------------------- ------------------------- --------------- -------------- ------------------------------------------------------------------
  Dick et al., [@B14]        Cardiogenics consortium   European        459            25.9(3.6)
                             MARTHA                    European        339            24.2(4.4)
                             KORA                      European        1,789          28.1(4.8)
  Pan et al., [@B27]         GUSTO cohort              Asian           991            1.3(0.1)[^b^](#TN2){ref-type="table-fn"}
  Aslibekyan et al., [@B4]   GOLDN                     EA              991            28(6)
                             ARIC                      AA              2,105          30(6)
  Al Muftah et al., [@B2]    Qatari cohort             Caucasian       123            28.3(6.2)
                             Twins UK cohort           Caucasian       810            27.8(5.2)
  Main et al., [@B22]        EUGENE2 Consortium        Caucasian       137            27.9(6.0)
  Wahl et al., [@B36]        LOLIPOP                   Asian           2,680          27.6(4.4)
                             EGCUT Asthma              European        173            22.8(3.0)
                             EGCUT CTG                 European        96             26.7(5.1)
                             ALSPAC                    European        701            26.6(5.3)
                             Twins UK                  European        338            26.7(5.0)
                             RS-III                    European        731            27.6(4.6)
                             Life Lines Deep           European        752            25.4(4.2)
                             Leiden Longevity          European        642            25.5(3.5)
                             RS-BIOS                   European        762            27.8(4.2)
                             LOLIPOP                   Asian           656            27.0(4.4)
  Mendelson et al., [@B24]   FHS                       European        2,377          28.3(5.4)
                             LBC 1936                  European        920            27.8(4.4)
                             LBC 1921                  European        446            26.2(4.0)
  Koh et al., [@B19]         KoCAS                     Asian           692            19.4(1.3)
  Wang et al., [@B37]        EpiGO                     AA              128            18.8(1.3)
                             LACHY                     AA              284            24.1(5.6)
                             BP stress cohort          AA              228            31.4(8.6)
  Dhana et al., [@B13]       RS                        European        1,450          27.7(4.4)
  Xu et al., [@B39]          Community volunteers      Mixed           510            24.5(2.9)

*Values are shown as mean ± SD*.

*BMI was derived as weight (g) divided by height^2^ (cm^2^)*.

*MARTHA, MARseille THrombosis Association; KORA, Cooperative Health Research; ARIC, Atherosclerosis Risk in Communities; GUSTO, Growing Up in Singapore toward Healthy Outcomes; FHS, Framingham Heart Study; EUGENE2, European Network on Functional Genomics of Type 2 Diabetes; ALSPAC, Avon Longitudinal Study of Parents and Children; RS-III, Rotterdam Study III; BIOS, Biobank-based Integrative Omics Studies; LOLIPOP, The London Life Sciences Prospective Population; LBC, Lothian Birth Cohort; KoCAS, Korean Child-Adolescent Cohort Study; EpiGO, Epigenetic Basis of Obesity-Induced Cardiovascular Disease and Type 2 Diabetes; LACHY: Lifestyle, Adiposity and Cardiovascular Health in Youth; BP, Blood pressure; RS, Rotterdam Study; AA, African American; EA, European American*.

Meta-Analysis and Pathway Enrichment Analysis
---------------------------------------------

A total of 13 articles were enrolled in our meta-analysis. The pooled peripheral blood samples for each CpG ranged from 700 to 18,370. We identified 119 CpGs associated with obesity, that reached a genome-wide significant level of *p* ≤ 1.03 × 10^−7^ (Supplementary Table 1). The top 10 associated CpGs are shown in Table [2](#T2){ref-type="table"}.

###### 

The top 10 associated CpGs in the meta-analysis.

  **CpG**      ***P***           ***N***   **Dir**                             **Gene[^a^](#TN3){ref-type="table-fn"}**
  ------------ ----------------- --------- ----------------------------------- ------------------------------------------
  cg06500161   4.76 × 10^−122^   16737     \+ + + + + + + + +                  *ABCG1*
  cg00574958   1.44 × 10^−98^    17748     --- --- --- --- --- --- ---         *CPT1A*
  cg11024682   5.01 × 10^−81^    17670     \+ + + + + + + + + + +              *SREBF1*
  cg07573872   2.22 × 10^−56^    18370     --- --- --- --- --- --- ---         *SBNO2*
  cg27243685   3.64 × 10^−55^    17274     \+ + + + + + + + + +                *ABCG1*
  cg18181703   1.73 × 10^−51^    13417     --- --- --- --- --- --- --- --- +   *SOCS3*
  cg09349128   2.39 × 10^−51^    13694     --- --- --- ---                     
  cg26403843   6.72 × 10^−46^    16737     \+ + + + + + + + +                  *RNF145*
  cg04927537   2.64 × 10^−44^    16737     \+ + + + + + + + +                  *LGALS3BP*
  cg06192883   2.51 × 10^−40^    16737     \+ + + + + + + + +                  *MYO5C*

*The genes were annotated using the default resources provided by Metascape*.

*CpG, Cytosine-phosphate-Guanine; P, P-value; N, the total sample size of the corresponding CpG sites; Dir, direction of association with body mass index*.

Seventy-eight genes were annotated to be affiliated with these CpGs and used as the input to the pathway enrichment analysis. These associated genes were enriched in three KEGG pathways related to insulin resistance, adipocytokine signaling and TNF signaling. However, none of them were significant after multiple testing corrections (FDR *p* \> 0.05). According to the KEGG, there is only one gene (*SOCS3*) which was involved in all three pathways (Table [3](#T3){ref-type="table"}).

###### 

Enriched KEGG pathway.

  **Description**                   ***P***         **FDR**   **Gene symbols**
  --------------------------------- --------------- --------- -------------------------------
  Insulin resistance                5.23 × 10^−4^   0.26      *CPT1A,RPS6KA2,SREBF1, SOCS3*
  Adipocytokine signaling pathway   1.77 × 10^−3^   0.44      *CPT1A,SOCS3,ACSBG1*
  TNF signaling pathway             6.27 × 10^−3^   1.00      *BCL3,MAP3K5,SOCS3*

*KEGG, Kyoto Encyclopedia of Genes and Genomes; P, P-value; FDR, false discovery rate*.

Differential Expression of the Affiliated Genes
-----------------------------------------------

We analyzed 30 VAT samples and 20 SAT samples to assess the differential expression of the affiliated genes. A *p* ≤ 0.05 and \|log~2~ (fold change)\| ≥1 were used as criteria for differentially expressed genes. In the SAT, a total of 392 differentially expressed genes were obtained, of which 317 were up-regulated and 75 were down-regulated. On the other hand, there were 875 differentially expressed genes in the VAT, of which 406 were up-regulated and 469 were down-regulated. Among the genes affiliated with the 119 significant CpGs, *SOCS3* and *DOK2* were differentially expressed in the SAT of obesity patients, while seven genes (*SOCS3, PRR5L, ABCG1, BRDT, B3GNT7, ZNF710*, and *RARRES1*) were differentially expressed in the VAT of obesity patients. It is worth mentioning that the *SOCS3* gene was up-regulated in both human SAT (log~2~ fold change = 1.06, *p* = 9.23 × 10^−3^) and VAT (log~2~ fold change = 1.92, *p* = 8.52 × 10^−3^). The results are detailed in Supplementary Tables 2, 3.

The Association With Obesity in Human VAT and Liver Tissue
----------------------------------------------------------

Twenty VAT samples and 15 liver tissue samples were analyzed to test whether the association in the peripheral blood samples can be transferred into the metabolic tissues. The results revealed that seven CpGs in 119 associated CpGs were significantly associated with obesity (*p* \< 0.05) in both the VAT and the liver tissue. The detailed results are shown in Table [4](#T4){ref-type="table"}. Interestingly, most of them were associated with obesity in the opposite direction in the VAT and the liver tissue. For example, the CpG site cg07136133 was hyper-methylated in the VAT (log~2~fold change = 0.135, *p* = 0.014), but hypo-methylated (log~2~ fold change = −0.066, *p* = 0.013) in the liver of obesity patients.

###### 

The association with obesity in human VAT and liver tissue.

  **CpG**      **peripheral blood**   **VAT**                   **Liver tissue**                             
  ------------ ---------------------- ------------------------- ------------------ -------- ------- -------- -------
  cg07136133   1.67 × 10^−35^         --- --- --- --- --- ---   *PRR5L*            0.135    0.014   −0.066   0.013
  cg07037944   1.43 × 10^−19^         --- --- --- ------ ---    *DAPK2*            0.059    0.026   −0.046   0.024
  cg22891070   4.93 × 10^−18^         \+ + + + + +              *HIF3A*            −0.140   0.008   −0.094   0.027
  cg09554443   2.58 × 10^−17^         --- --- --                *CD247*            0.078    0.016   −0.038   0.035
  cg00741986   1.38 × 10^−8^          --- ---                   *TNIP2*            0.076    0.012   −0.065   0.016
  cg15011409   2.23 × 10^−8^          \+ + +                    *ICAM5*            −0.073   0.009   0.067    0.013
  cg03257930   6.24 × 10^−8^          --- ---                                      0.109    0.040   −0.056   0.010

*The genes were annotated using the default resources provided by Metascape*.

*CpG, Cytosine-phosphate-Guanine; VAT, visceral adipose tissue; P, P-value; Dir, direction of association with body mass index; Logfc, log fold change*.

Discussion {#s4}
==========

In this study, we identified 119 obesity-associated DNA methylations in human peripheral blood samples by combining results from previous studies. We further implemented the integrative approach highlighting *SOCS3* among the numerous associated genes as a promising drug target.

The role of *SOCS3* in obesity was strongly supported by our pathway enrichment analysis and the differential gene expression in the metabolic tissues. The pathway enrichment analysis is an efficient tool for drug target discovery (Aguirre-Plans et al., [@B1]). A gene which was involved in each or most of the enriched pathways may be situated in an essential position in the etiology of obesity. In our results, *SOCS3* was the only obesity-associated gene whose protein regulated all three of the most enriched KEGG pathways. SOCS3 suppresses the target proteins by promoting their ubiquitination and degradation. Those included insulin receptor substrates (IRS1 and IRS2) in the liver cells and the leptin receptor (LEPR) in adipocytes (Bjorbak et al., [@B5]; Eyckerman et al., [@B16]; Rui et al., [@B30]; Howard et al., [@B18]). In our study, *SOCS3* gene expression was up-regulated in both the VAT and SAT of obesity patients. This observation is in line with the increased insulin resistance found in morbid obesity patients and it further confirmed SOCS3 as a promising drug target (Mitrou et al., [@B25]; Dawson et al., [@B9]; Pucci et al., [@B28]).

Although involved in the insulin signaling pathway, the association between *SOCS3* DNA methylation and type 2 diabetes (T2D) has been under debate. In studies of a small sample size (*N* \< 300), the *SOCS3* CpG was not associated with T2D (*p* \> 0.05), with or without the adjustment of the BMI (Al Muftah et al., [@B2]; Dayeh et al., [@B10]). Furthermore, it is even associated with a BMI with the adjustment of T2D in one of the studies using the same cohort (Dayeh et al., [@B10]). In a study with 1074 incident T2D samples and 1590 controls, the *SOCS3* CpG was associated with incident T2D (*p* = 1.2 × 10^−7^) without the adjustment of the BMI (Chambers et al., [@B6]).

On the other hand, it has also been considered controversial whether the obesity-associated *SOCS3* CpG impacts the transcription level. It was demonstrated that the hypo-methylation at the associated *SOCS3* CpG may induce higher SOCS3 expression in peripheral blood mononuclear cells (Ali et al., [@B3]). One might think that this is probably transferable to other tissues, however, the hypo-methylation at this CpG was found to be related to lower gene expression in the human pancreatic islet but related to higher gene expression in adipose tissue (Dayeh et al., [@B10]). This apparently controversial evidence has indicated that the regulation of SOCS3 expression might be much more complex than we previously thought. Further investigation is necessary to uncover the tissue-specific modifier of expression regulation of this gene and to understand whether this helps to clarify the association between *SOCS3* DNA methylation and T2D.

DNA methylations in peripheral blood samples could be different from those in metabolic tissues, like adipose tissue and liver cells (De Bustos et al., [@B11]; Lovinsky-Desir et al., [@B21]). The conclusion derived from non-metabolic tissues should be validated in multiple metabolic tissues, before being used as evidence to support drug development or clinical trials. However, the GEO DNA methylation datasets in metabolic tissues had a small sample size. A statistical power analysis showed that we only had 9.5% power to detect a weak effect of DNA methylation on obesity using 20 samples. We hope that a better powered DNA methylation analysis in metabolic tissues could be taken into consideration in future integrative studies.

As compared to *SOCS3*, other genes showed a relatively weak relevance in our integrative analysis. The DNA methylation of the *ABCG1* gene was the top signal in peripheral blood samples. Unfortunately, the *ABCG1* gene was only differentially expressed in the VAT of obesity patients. The *CPT1A* gene was involved in two enriched pathways, but not differentially expressed in adipose tissues. Except for *SOCS3, CPT1A*, and *ABCG1*, other top 10 associated genes, shown in Table [2](#T2){ref-type="table"}, lacked evidence of differential expression in adipose tissues and involvement in the enriched pathways. When taking a closer look at the 119 associated genes, we did have five additional differentially expressed genes in the VAT and one in the SAT. However, their priority was not supported by the enriched pathways.

The strength of this study lies in overlapping multiple lines of evidence to prioritize the candidate genes for drug target development, from the many associated DNA methylations. The integrated approach included genome-wide screening results in peripheral blood samples, pathway enrichment analysis, and differential gene expression in multiple adipose tissues. Screening obesity-associated CpGs in peripheral blood is remains the most practical way currently, as peripheral blood samples are abundant in many research groups. However, it should be noted that genomic DNA methylation can vary among different tissue types. For example, from our DNA methylation analyses in metabolic tissues, we observed the opposite direction of association at most of the associated CpGs (Table [4](#T4){ref-type="table"}).

It should be noted that our study had limitations. Firstly, the association results from the included studies, came with various types of data transformation and statistical models, the effect sizes showed strong heterogeneity. We combined the *p*-values using a sample-size-weighted strategy, which is a flexible approach, but can also be inaccurate. The genome-wide screening of our pipeline could be improved when the individual DNA methylation data is available. Secondly, we analyzed the GEO datasets using the GEO2R tool. This tool was not able to adjust for the covariates, e.g., age and sex, which may be helpful in minimizing the effects from confounding factors. Finally, the included GEO datasets have much smaller sample sizes as compared to the genome-wide screening, which may have increased the false negative rate of our approach.

Conclusion {#s5}
==========

In summary, we integrated multiple lines of evidence to reveal candidate genes for the treatment of obesity and its complications. Our study provided new insights on the interaction between obesity and the epigenome. Future studies are warranted to discover more potential drug targets using larger sample sizes from metabolic tissues, and to elucidate the mechanism of *SOCS3* DNA methylation interacting with obesity.
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###### 

Click here for additional data file.

ABCG1

:   ATP Binding Cassette Subfamily G Member 1

BMI

:   body mass index

CpG

:   Cytosine-phosphate-Guanine

FDR

:   false discovery rate

GWAS

:   Genome Wide Association Study

IRS1

:   insulin receptor substrate 1

IRS2

:   insulin receptor substrate 2

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

LEPR

:   leptin receptor

SAT

:   subcutaneous adipose tissue

SOCS3

:   Suppressor Of Cytokine Signaling 3

T2D

:   type 2 diabetes

VAT

:   visceral adipose tissue.
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